Pharmacovigilance [Pharmacovigilance update]

Details

Serval ID
serval:BIB_FB76F57165B0
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Pharmacovigilance [Pharmacovigilance update]
Journal
Revue medicale suisse
Author(s)
Livio F.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Publication state
Published
Issued date
10/01/2018
Peer-reviewed
Oui
Volume
14
Number
588-589
Pages
81-84
Language
french
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Abstract
The main pharmacovigilance updates in 2017 are reviewed. Denosumab : rebound-associated multiple vertebral fractures after discontinuation. Canagliflozine: increased risk of foot/leg amputations. Biologic and targeted cancer therapies, direct-acting antivirals for chronic hepatitis C: risk of hepatitis B reactivation. Checkpoint inhibitors : immune-related adverse events and graft rejection. Fingolimod : rebound-associated reactivation of MS following withdrawal. Daclizumab: risk of severe liver injury leading to restricted use in MS patients. Posaconazole: risk of overexposure when switching from oral suspension to tablets. Voriconazole: cutaneous squamous cell carcinoma under long-term therapy. Proton pump inhibitors : early exposure might increase fracture risk in young children.
Keywords
Carcinoma, Squamous Cell/drug therapy, Child, Denosumab/adverse effects, Humans, Pharmacovigilance, Skin Neoplasms/drug therapy, Spinal Fractures/chemically induced
Pubmed
Create date
25/01/2018 20:32
Last modification date
17/09/2020 8:24
Usage data